FDA, Amarin Bash Watson's Bid To Join Exclusivity Fight
The U.S. Food and Drug Administration and Amarin Pharmaceuticals Ireland Ltd. attacked efforts by Watson Laboratories Inc. to appeal a recent D.C. federal court decision on exclusivity for omega-3 drug Vascepa,...To view the full article, register now.
Already a subscriber? Click here to view full article